PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.
PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.
Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.
The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.
This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.
A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).
|PGx Test||Variants Assayed||Related Drugs?|
|Alternate Names:||nuclear receptor subfamily 2 group B member 1|
|Alternate Symbols: ||NR2B1|
|PharmGKB Accession Id:||PA34890|
|Cytogenetic Location:||chr9 : q34.3 - q34.2|
|GP mRNA Boundary†:||chr9 : 137218316 - 137332431|
|GP Gene Boundary†:||chr9 : 137208316 - 137335431|
PharmGKB Curated Pathways
Pathways created internally by PharmGKB based primarily on literature evidence.
PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.
Links to non-PharmGKB pathways.
- basic mechanism of action of ppara pparb(d) and pparg and effects on gene expression - (BioCarta via Pathway Interaction Database)
- control of gene expression by vitamin d receptor - (BioCarta via Pathway Interaction Database)
- degradation of the rar and rxr by the proteasome - (BioCarta via Pathway Interaction Database)
- map kinase inactivation of smrt corepressor - (BioCarta via Pathway Interaction Database)
- mechanism of gene regulation by peroxisome proliferators via ppara - (BioCarta via Pathway Interaction Database)
- nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription in carcinoma cells - (BioCarta via Pathway Interaction Database)
- Retinoic acid receptors-mediated signaling - (Pathway Interaction Database NCI-Nature Curated)
- role of ppar-gamma coactivators in obesity and thermogenesis - (BioCarta via Pathway Interaction Database)
- RXR and RAR heterodimerization with other nuclear receptor - (Pathway Interaction Database NCI-Nature Curated)
- transcription regulation by methyltransferase of carm1 - (BioCarta via Pathway Interaction Database)
- visceral fat deposits and the metabolic syndrome - (BioCarta via Pathway Interaction Database)
Publications related to RXRA: 5
The following icons indicate that data of a certain type is available:
- DG Dosing Guideline information is available
- DL Drug Label information is available
- CA High-level Clinical Annotation is available
- VA Variant Annotation is available
- VIP VIP information is available
- PW Pathway is available
[ close ]
||Association between polymorphic variation in VDR and RXRA and circulating levels of vitamin D metabolites. The Journal of steroid biochemistry and molecular biology. 2010. Hibler E A, et al.|
||Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS computational biology. 2009. Xie Li, et al.|
||Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. The Journal of biological chemistry. 2002. Kast Heidi R, et al.|
||SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes & development. 1998. Blumberg B, et al.|
||The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. The Journal of clinical investigation. 1998. Lehmann J M, et al.|